$100 million NuvaRing settlement finalized

June 5, 2014

A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that enough claimants have chosen to opt into the agreement.

U.S. District Judge Rodney W. Sippel of St. Louis approved the in February, but NuvaRing maker Merck & Co. had the right to abandon the deal if less than 95 percent of claimants opted in.

Attorneys for the claimants and Merck said Thursday that the 95 percent threshold has been reached. St. Louis attorney Roger Denton, lead lawyer for those who sued, says about 3,800 claimants will share in the settlement.

The lawsuits allege faulty design and testing, and claim that potential hazards of the device were not adequately disclosed.

Merck says there is "substantial" evidence to show that NuvaRing is safe.

Explore further: Merck will pay $950M to settle Vioxx investigation

Related Stories

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.